PAM
AGIO icon

Paradigm Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Paradigm Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,900
Closed -$201K – 417
2017
Q2 		$201K Sell
3,900
-4,100
-51% -$210K 0.04% 344
2017
Q1 		$467K Sell
8,000
-1,300
-14% -$62.3K 0.09% 277
2016
Q4 		$388K Sell
9,300
-300
-3% -$15.7K 0.07% 217
2016
Q3 		$507K Buy
9,600
+500
+5% +$21.8K 0.09% 253
2016
Q2 		$381K Buy
9,100
+300
+3% +$14.8K 0.07% 266
2016
Q1 		$357K Hold
8,800
– – 0.07% 260
2015
Q4 		$571K Sell
8,800
-15,300
-63% -$1M 0.1% 200
2015
Q3 		$1.7M Sell
24,100
-6,300
-21% -$616K 0.22% 138
2015
Q2 		$3.38M Hold
30,400
– – 0.38% 87
2015
Q1 		$2.87M Buy
30,400
+7,100
+30% +$796K 0.32% 102
2014
Q4 		$2.61M Buy
+23,300
New +$2.08M 0.34% 108

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paradigm Asset Management's AGIO Position: Q3 2017 in Review

Paradigm Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 3,900 shares — an estimated $201K sold.

Paradigm Asset Management first reported a position in AGIO in Q4 2014 and held it in 11 quarters. The position peaked at $3.38M in Q2 2015. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

  • Paradigm Asset Management reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Paradigm Asset Management sold 3,900 Agios Pharmaceuticals shares in Q3 2017, an estimated $201K.
  • Paradigm Asset Management first reported a position in Agios Pharmaceuticals in Q4 2014 and held it in 11 quarters.
  • Paradigm Asset Management's Agios Pharmaceuticals position peaked at $3.38M in Q2 2015.
  • 171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.